Clinical Trial Update: Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating radiation/temozolomide with daratumumab immunotherapy for glioblastoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Daratumumab (daratumumab)
• Temodar (Temozolomide)

Snippet

Sponsor: West Virginia University | Conditions: Glioblastoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING